HUME DANIEL 4
4 · STEMLINE THERAPEUTICS INC · Filed Jun 10, 2020
Insider Transaction Report
Form 4
HUME DANIEL
Director
Transactions
- Disposition from Tender
Common Stock
2020-06-10−35,468→ 0 total
Footnotes (1)
- [F1]Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.